Baxter International (BAX)
(Delayed Data from NYSE)
$39.65 USD
+0.13 (0.33%)
Updated Apr 18, 2024 04:00 PM ET
After-Market: $39.67 +0.02 (0.05%) 7:28 PM ET
3-Hold of 5 3
A Value D Growth B Momentum C VGM
Company Summary
Headquartered in Deerfield, IL, Baxter International Inc. is a global medical technology company. The company is engaged in the development, manufacture and sale of a broad range of products, digital health solutions and therapies used by hospitals and other care-giving organizations including at-home physician supervision. Currently, the company has presence in more than 100 countries.
Baxter has been reporting its legacy business under three segments based on geography of operations — Americas, EMEA and APAC — and a global segment for Hillrom business that was acquired in 2021.
...
Company Summary
Headquartered in Deerfield, IL, Baxter International Inc. is a global medical technology company. The company is engaged in the development, manufacture and sale of a broad range of products, digital health solutions and therapies used by hospitals and other care-giving organizations including at-home physician supervision. Currently, the company has presence in more than 100 countries.
Baxter has been reporting its legacy business under three segments based on geography of operations — Americas, EMEA and APAC — and a global segment for Hillrom business that was acquired in 2021.
Baxter reports through 10 product categories. Renal Care (24.9% of net sales in 1H23), Medication Delivery (19.7%), Pharmaceuticals (14.6%), Clinical Nutrition (6.3%), Advanced Surgery (7%), Acute Therapies (4.9%), Patient Support Systems (9.6%), Front Line Care (8.3%), Global Surgical Solutions (2.1%) and Other (0.7%).The last three categories were added with Hillrom acquisition.
Baxter’s Renal category primarily consists of Peritoneal Dialysis (PD) and Hemodialysis (HD) therapies. The Medication Delivery category includes sales of our intravenous (IV) therapies, and infusion pumps. The Pharmaceuticals mainly comprises premixed and oncology drug platforms, inhaled anesthesia and critical care products. The Clinical Nutrition category has parenteral nutrition therapies. The biological products and medical devices used in surgical procedures for hemostasis are primary products in the Advanced Surgery category. The company’s continuous renal replacement therapies (CRRT) and other organ support therapies focused in the intensive care unit (ICU) are part of Acute Therapies category. The Patient Support Systems category consists of connected care solutions including devices, software, communications and integration technologies and smart bed. All integrated patient monitoring and diagnostic technologies are part of Front Line Care category. The Global Surgical Solutions category include surgical solutions like video technologies, tables, lights, pendants and precision positioning devices.
2023 at a Glance: Baxter reported net revenues of $14.81 billion in 2023, up 2% year over year on a reported basis. Adjusted earnings were down 14% to $2.60 per share.
General Information
Baxter International Inc
One Baxter Parkway DF2-1W
Deerfield, IL 60015
Phone: 224-948-2000
Fax: 224-948-1813
Email: global_corp_investor_relations@baxter.com
| Industry | Medical - Products |
| Sector | Medical |
| Fiscal Year End | December |
| Last Reported Quarter | 3/31/2024 |
| Earnings Date | 5/2/2024 |
EPS Information
| Current Quarter EPS Consensus Estimate | 0.61 |
| Current Year EPS Consensus Estimate | 2.89 |
| Estimated Long-Term EPS Growth Rate | 6.40 |
| Earnings Date | 5/2/2024 |
Price and Volume Information
| Zacks Rank |  |
| Yesterday's Close | 39.52 |
| 52 Week High | 50.21 |
| 52 Week Low | 31.32 |
| Beta | 0.62 |
| 20 Day Moving Average | 3,173,515.00 |
| Target Price Consensus | 45.00 |
| 4 Week | -5.52 |
| 12 Week | 4.33 |
| YTD | 2.22 |
| 4 Week | -1.71 |
| 12 Week | 1.14 |
| YTD | -2.91 |
| Shares Outstanding (millions) | 507.83 |
| Market Capitalization (millions) | 20,069.34 |
| Short Ratio | NA |
| Last Split Date | 5/31/2001 |
| Dividend Yield | 2.94% |
| Annual Dividend | $1.16 |
| Payout Ratio | 0.43 |
| Change in Payout Ratio | 0.11 |
| Last Dividend Payout / Amount | 2/29/2024 / $0.29 |
Fundamental Ratios
| P/E (F1) | 13.68 |
| Trailing 12 Months | 14.64 |
| PEG Ratio | 2.13 |
| vs. Previous Year | 0.00% |
| vs. Previous Quarter | 29.41% |
| vs. Previous Year | -0.05% |
| vs. Previous Quarter | 4.77% |
| Price/Book | 2.37 |
| Price/Cash Flow | 7.54 |
| Price / Sales | 1.34 |
| 3/31/24 | NA |
| 12/31/23 | 19.49 |
| 9/30/23 | 21.38 |
| 3/31/24 | NA |
| 12/31/23 | 4.77 |
| 9/30/23 | 4.76 |
| 3/31/24 | NA |
| 12/31/23 | 1.48 |
| 9/30/23 | 1.94 |
| 3/31/24 | NA |
| 12/31/23 | 1.04 |
| 9/30/23 | 1.48 |
| 3/31/24 | NA |
| 12/31/23 | 9.19 |
| 9/30/23 | 9.16 |
| 3/31/24 | NA |
| 12/31/23 | 17.77 |
| 9/30/23 | 17.34 |
| 3/31/24 | NA |
| 12/31/23 | -0.70 |
| 9/30/23 | -1.36 |
| 3/31/24 | NA |
| 12/31/23 | 16.69 |
| 9/30/23 | 16.10 |
| 3/31/24 | NA |
| 12/31/23 | 3.42 |
| 9/30/23 | 3.44 |
| 3/31/24 | NA |
| 12/31/23 | 1.31 |
| 9/30/23 | 1.72 |
| 3/31/24 | NA |
| 12/31/23 | 56.79 |
| 9/30/23 | 63.27 |